U.S. market Closed. Opens in 10 hours 5 minutes

FNA | Paragon 28, Inc. Stock Overview

(Stock Exchange: NYSE)
Day's Range 5.63 - 6.29
52 Week Range 4.65 - 14.79
Beta 0.98
Implied Volatility 111.14%
IV Rank 79.70%
Day's Volume 589,277
Average Volume 492,495
Shares Outstanding 83,542,290
Market Cap 506,266,277
Sector Healthcare
Industry Medical - Devices
IPO Date 2021-10-15
Valuation
Profitability
Growth
Health
P/E Ratio -9.18
Forward P/E Ratio N/A
EPS -0.66
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 574
Country USA
Website FNA
Paragon 28, Inc. designs, develops, distributes, and sells foot and ankle surgical systems in the United States and internationally. It offers plating systems, including gorilla plating systems, such as lisfranc, lapidus, lateral column, calcaneus slide, and naviculocuneiform (NC) fusion plating systems; baby gorilla plate-specific screws, navicular fracture plates, and 5th metatarsal hook plates; and silverback plating systems. The company also provides precision guide technology for various procedures consisting of fusion, a procedure to address bunion deformities that fuses two bones on the big toe; first tarsometatarsal arthrodesis; and metatarsal osteotomy for bunion correction, medial column beaming for charcot foot reconstruction, ankle fusion plating, and NC joint arthrodesis. In addition, it offers monster, mini monster, and joust beaming screw systems for use in bone reconstruction, osteotomy, arthrodesis, joint fusion, ligament fixation, fracture repair, and fracture fixation; and APEX 3D total ankle replacement systems; total talus spacers to replace the talus and bone in the ankle that connects the leg and foot. Further, the company provides bunion or hallux valgus correction systems, including nail systems phantom intramedullary nail systems for the treatment of severe hallux valgus; and various orthobiologics comprising bone wedges, grafts, demineralized bone matrices, bone void fillers, synthetic materials, amniotic products, and a biocompatible collagen matrix, as well as PRESERVE bone graft systems for homologous application. Additionally, it offers soft tissue fixation systems, titanium sprayed polyetheretherketone implants, nitinol staple systems, stabilization systems, and curved instruments. The company serves hospitals and ambulatory surgery centers through a network of sales representatives and stocking distributors. Paragon 28, Inc. was founded in 2010 and is headquartered in Englewood, Colorado.
*Chart delayed
Analyzing fundamentals for FNA we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is very weak. For more detailed analysis please see FNA Fundamentals page.

Watching at FNA technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, but short-term trend is bullish. More technicals details can be found on FNA Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙